Denali Therapeutics Stock Probability of Future Stock Price Finishing Under 18.26

DNLI Stock  USD 16.11  0.12  0.75%   
Denali Therapeutics' implied volatility is one of the determining factors in the pricing options written on Denali Therapeutics. Implied volatility approximates the future value of Denali Therapeutics based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in Denali Therapeutics over a specific time period. For example, 2024-05-17 CALL at $15.0 is a CALL option contract on Denali Therapeutics' common stock with a strick price of 15.0 expiring on 2024-05-17. The contract was last traded for $1.85 and, as of today, has 23 days remaining before the expiration. The option is currently trading at a bid price of $1.4, and an ask price of $2.7. The implied volatility as of the 24th of April is 89.85. View All Denali options

Closest to current price Denali long CALL Option Payoff at Expiration

Denali Therapeutics' future price is the expected price of Denali Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Denali Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Denali Therapeutics Backtesting, Denali Therapeutics Valuation, Denali Therapeutics Correlation, Denali Therapeutics Hype Analysis, Denali Therapeutics Volatility, Denali Therapeutics History as well as Denali Therapeutics Performance.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
  
The Denali Therapeutics' current Price Earnings To Growth Ratio is estimated to increase to 0.36, while Price To Sales Ratio is projected to decrease to 8.47. Please specify Denali Therapeutics' target price for which you would like Denali Therapeutics odds to be computed.

Denali Therapeutics Target Price Odds to finish below 18.26

The tendency of Denali Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 18.26  after 90 days
 16.11 90 days 18.26 
about 43.13
Based on a normal probability distribution, the odds of Denali Therapeutics to stay under $ 18.26  after 90 days from now is about 43.13 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) . Probability of Denali Therapeutics price to stay between its current price of $ 16.11  and $ 18.26  at the end of the 90-day period is about 34.33 .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.42 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Denali Therapeutics will likely underperform. Additionally Denali Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   Denali Therapeutics Price Density   
       Price  

Predictive Modules for Denali Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Denali Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Denali Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
10.0416.1122.18
Details
Intrinsic
Valuation
LowRealHigh
8.9214.9921.06
Details
Naive
Forecast
LowNextHigh
9.2315.3021.36
Details
17 Analysts
Consensus
LowTargetHigh
50.6055.6061.72
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Denali Therapeutics. Your research has to be compared to or analyzed against Denali Therapeutics' peers to derive any actionable benefits. When done correctly, Denali Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Denali Therapeutics.

Denali Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Denali Therapeutics is not an exception. The market had few large corrections towards the Denali Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Denali Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Denali Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.24
β
Beta against NYSE Composite3.42
σ
Overall volatility
1.83
Ir
Information ratio -0.0053

Denali Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Denali Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Denali Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Denali Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M).
Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Over 79.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: An Intrinsic Calculation For Denali Therapeutics Inc. Suggests Its 44 percent Undervalued

Denali Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Denali Stock often depends not only on the future outlook of the current and potential Denali Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Denali Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding137.4 M
Cash And Short Term InvestmentsB

Denali Therapeutics Technical Analysis

Denali Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Denali Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Denali Therapeutics. In general, you should focus on analyzing Denali Stock price patterns and their correlations with different microeconomic environments and drivers.

Denali Therapeutics Predictive Forecast Models

Denali Therapeutics' time-series forecasting models is one of many Denali Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Denali Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Denali Therapeutics

Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Denali Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M).
Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Over 79.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: An Intrinsic Calculation For Denali Therapeutics Inc. Suggests Its 44 percent Undervalued
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.06)
Revenue Per Share
2.406
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.09)
Return On Equity
(0.14)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.